|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest a role for CDKN2A/B and FHIT in early progression of BE to dysplasia and adenocarcinoma that warrants future mechanistic research.
|
31001805 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a two-stage study design including discovery and replication studies, and stringent Bonferroni correction for multiple statistical analysis, we identified significant genetic interactions between SNPs in <i>RGL1:RAD51B</i> (OR=0.44, <i>p</i> value=3.27x10<sup>-11</sup> in overall lung cancer and OR=0.41, <i>p</i> value=9.71x10<sup>-11</sup> in non-small cell lung cancer), <i>SYNE1:RNF43</i> (OR=0.73, <i>p</i> value=1.01x10<sup>-12</sup> in adenocarcinoma) and <i>FHIT:TSPAN8</i> (OR=1.82, <i>p</i> value=7.62x10<sup>-11</sup> in squamous cell carcinoma) in our analysis.
|
30956756 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Most of the samples (54.0%) were negative for FHIT protein, 26.4% adenocarcinomas showed a weak to moderate immunostaining and 19.6% adenocarcinomas showed strong FHIT immunostaining.
|
24370550 |
2014 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Immunohistochemically, PTEN expression gradually decreased from small cell carcinomas (SCCs), through large cell carcinomas (LCCs) and adenocarcinomas (ADs) to squamous (SQ) cell carcinomas (p <0.05), whereas FHIT was more highly expressed in ADs and LCCs, compared with SQs and SCCs (p <0.05).
|
17348444 |
2007 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The positive of FHIT gene expression in normal colorectal tissue, adenoma and adenocarcinoma were 93.75%, 68.75% and 46.25%, respectively.
|
17382535 |
2006 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicated that the high frequency of FHIT gene disruption was important in the development of both squamous cell carcinomas and adenocarcinomas.
|
15150628 |
2004 |
|
Adenocarcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of the FHIT gene occurred more frequently in squamous cell carcinoma than adenocarcinoma.
|
15231689 |
2004 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results indicated that changes in the Fhit gene occurred frequently and thus may have played a role in the development of pancreatic duct adenocarcinomas induced by BOP in hamsters.
|
12557261 |
2003 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together, our data indicate that the FHIT gene expression is frequently altered in gastric adenocarcinomas by aberrant splicing, and suggest that different types of aberrant transcripts may result during the multi-step splice processing.
|
11642547 |
2001 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To correlate DNA and RNA lesions of the FHIT gene with the effect on FHIT protein expression, we have investigated the FHIT gene for loss of heterozygosity (LOH), aberrant transcripts, point mutations, and protein expression in 35 gastric adenocarcinomas.
|
11396980 |
2001 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Most notably, loss of normal FHIT transcript and impaired expression of Fhit protein occurred only in serous adenocarcinomas of grade 2 and 3 (5/15; 33% and 6/19; 32%, respectively).
|
11461085 |
2001 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas.
|
10912665 |
2000 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, loss or reduced expression of fhit protein was observed in 13/27 (48%) endometrial adenocarcinomas.
|
10652418 |
2000 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated FHIT gene involvement in 39 esophageal carcinomas (18 adenocarcinomas [AC¿, 21 squamous cell carcinomas [SCC]) by both reverse transcriptase-polymerase chain reaction (RT-PCR) amplification and loss of heterozygosity analysis (LOH).
|
10812172 |
2000 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas.
|
10679912 |
2000 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Forty-five colorectal adenocarcinomas were examined for alterations in the HIT family genes FHIT and PKCI-1/HINT by a combination of reverse transcriptase polymerase chain reaction and DNA sequencing.
|
10555761 |
1999 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of genomic DNA from 20 patients showed homozygous deletions involving exon 5 of FHIT in 4/20 (20%) esophageal adenocarcinomas, and 7/20 (35%) tumors demonstrated hemizygous loss.
|
9349498 |
1997 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Several microsatellite markers that precisely define the 1.0-Mb region surrounding FRA3B and FHIT have been utilized, along with other 3p microsatellites, to analyze the loss of 3p sequences in 25 primary pancreatic adenocarcinomas.
|
8813121 |
1996 |